Brookline has increased its price target for Immunic (IMUX, Financial) from $19 to $22, maintaining a Buy rating on the stock. This decision follows the company's release of promising data from its Phase 2 CALLIPER trial, which tested vidofludimus calcium, a nuclear receptor related 1 activator, in patients with progressive multiple sclerosis. The results align with Brookline's expectations and are seen as significantly reducing the development risk, according to the analyst.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for Immunic Inc (IMUX, Financial) is $14.17 with a high estimate of $28.00 and a low estimate of $5.00. The average target implies an upside of 1,302.64% from the current price of $1.01. More detailed estimate data can be found on the Immunic Inc (IMUX) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, Immunic Inc's (IMUX, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
